{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-073763","form_type":"8-K/A","ticker":null,"cik":"0001499785","company_name":"Tengjun Biotechnology Corp.","filed_at":"2023-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.108433+00:00","generated_at":"2026-06-10T23:55:30.943386+00:00","sec_items":["4.02","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tengjun Biotechnology restates FY2022 financials; appoints Caihong Qu as interim CEO/CFO after CEO death","bullets":["Board concluded FY2022 financial statements should no longer be relied upon due to accounting methodology errors.","Auditor discovered discrepancies in Q2 review, citing errors in recognition, measurement, and recording.","Company will amend FY2022 Form 10-K as soon as practicable to correct the errors.","Caihong Qu, age 48, appointed as director, interim CEO and CFO effective August 10, 2023.","Qu replaces Xianchang Ma, who passed away on August 3, 2023; she is his late wife."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-073763","json":"https://secwatch.observer/filing/0001213900-23-073763.json","markdown":"https://secwatch.observer/filing/0001213900-23-073763.md","text":"https://secwatch.observer/filing/0001213900-23-073763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/ea184679-8ka1_tengjun.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:55:30.943386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da378793dcdbcb9565aeb615c5b78a83ae1abe29","claim":"Tengjun Biotechnology Corp. reported that prior financial statements should not be relied upon.","evidence_excerpt":"On August 10, 2023, Tengjun Biotechnology Corp. (the \"Company\") announced that its Board of Directors (the \"Board\") concluded that the Company's previously issued financial statements, contained within its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, should no longer be relied upon due to accounting methodology errors in such financial statements and that the Board deems it advisable and in the best interests of the Company to restate the financial statements by amending its annual report on Form 10-K for the fiscal year ended December 31, 2022 as soon as reasonably practicable.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm","confidence":0.95,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"}],"fact_type":"auditor_change"},{"claim_id":"5b46ef2ef5","claim":"Xianchang Ma departed as Director, Chief Executive Officer and Chief Financial Officer at Tengjun Biotechnology Corp..","evidence_excerpt":"who passed away on August 3, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"passed away"},{"label":"Role","value":"Director, Chief Executive Officer and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"869a7e3837","claim":"Caihong Qu was appointed as Member of the Board at Tengjun Biotechnology Corp..","evidence_excerpt":"On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"},{"claim_id":"9201ef7898","claim":"Caihong Qu was appointed as interim Chief Executive Officer and Chief Financial Officer at Tengjun Biotechnology Corp..","evidence_excerpt":"On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1499785/000121390023073763/0001213900-23-073763-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Executive Officer and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}